02/27/2022

FDA has accepted the NDA for SP001

The first NDA (SP001) of the company had been submitted on December 25,  2021.  After 60 days reviewing, FDA has accepted the NDA.

06/017/2021

Dr. Yulu Wang gave a keynote speech at Chongqing 505b2 and Advanced Finished Dosage Summit 2021

6/17/2021 Dr. Yulu Wang gave a keynote speech on the current status, strategies and prospects of the research and development of improved new drug industries in China and the United States at the Chongqing 505b2 and Advanced Finished Dosage Summit 2021. 

View the presentation

06/07/2021

Grant of Patent Announced

SPES today announced the issuance of the U.S., China and PCT patent of Compositions of SP001 and Methods of Preparation

01/28/2021

New Commercial Partner Announced

On January 28, 2021, SPES Pharmaceuticals and Shanghai Yikangyong Pharmaceutical Technology Co., Ltd. (YKY) signed a strategic cooperation agreement to jointly develop the Chinese market.

 

SPES will sell its developed and authorized drugs in China through YKY's network. At the same time, YKY uses its network of medical experts to give SPES full assistance in product design, project research and clinical development.

 

About Shanghai Yikangyong Pharmaceutical Technology Co., Ltd.

 

Shanghai Yikangyong Pharmaceutical Technology Co., Ltd. is a medical service company that provides marketing, sales, and clinical development of drugs and medical devices. The main sales areas include nervous system drugs, antibiotics and other special drugs. YKY also has fully owned chain pharmacies in Shanghai, Zhejiang, Jiangxi and other provinces, and can provide patients with overseas drug purchase services.